Alexander Vartanov, MD

Alexander Vartanov, MD

Assistant Professor, Department of Bone Marrow Transplant & Cellular Therapies

Specialties

  • Hematology Oncology
  • Cellular Therapy
  • Blood and Marrow Transplant

Treatment Focus

  • Stem Cell Transplant
  • Cellular Therapies
  • Leukemia
  • Myelodysplastic Syndrome 
  • Lymphoma
  • Multiple Myeloma
  • Myeloproliferative Neoplasms

Treatment Philosophy

I believe in a patient-focused approach to medical care. My goal for each patient encounter is to educate and advise as I would my own family and to listen to my patients and their support team to understand how I can best help. Together we can develop the appropriate treatment plan, synthesize the latest developments in the field, and determine the optimal strategy for treatment.

I am delighted to work with knowledgeable and experienced colleagues to help me grow in the field. Our entire clinical and support staff create a positive and welcoming culture so that we can all deliver the best care to our patients.

Clinical Locations

  • Fox Chase-Temple University Hospital Bone Marrow Transplant Program
    7600 Central Avenue
    Patient Care Center, Fifth Floor
    Philadelphia, PA 19111
    Phone: 888-369-2427

Educational Background

  • Hematology/Oncology Fellowship 7/2021 – 6/2024 Temple University/Fox Chase Cancer Center Philadelphia, PA
  • Internal Medicine Residency, 6/2018 – 6/2021 , University of Connecticut New Britain, CT, Primary Care Internal Medicine (PCIM)
  • Master of Applied Science (MAS) 8/2016 – 5/2020 Johns Hopkins University Bloomberg School of Public Health Baltimore, MD Spatial Analysis for Public Health
  • Doctor of Medicine (MD) 5/2014 – 5/2018 American University of the Caribbean School of Medicine St. Maarten 
  • Bachelor of Arts (BA), 8/2006 – 5/2010, Wesleyan University Middletown, CT, Double Major: Physics, Chemistry

Certifications

  • American Board of Internal Medicine - Internal Medicine

Honors & Awards

  • 2019 Abstract Achievement Award, American Society of Hematology Annual Meeting 
  • 2019 Intern of the Year, Faculty Award, University of Connecticut PCIM

Selected Publications

Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L, Zhang W, Vartanov AR, Fernandes SM, Goldstein NR, Folco EG, Cibulskis K, Tesar B, Sievers QL, Shefler E, Gabriel S, Hacohen N, Reed R, Meyerson M, Golub TR, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ. SF3B1 and other Novel Cancer Genes in Chronic Lymphocytic Leukemia. New England Journal of Medicine. 2011 Dec 29; 365(26):2497-506.

Brown JR, Hanna M, Tesar B, Pochet N, Vartanov A, Fernandes SM, Werner L, Ash M, Roden CA, Macconaill L, Hainz U, Longtine J, Wang YE, Correll M, Van de Peer Y, Regev A, Wu C, Neuberg D, Freedman AS. Germline Copy Number Variation Associated with Mendelian Inheritance of CLL in Two Families. Leukemia. 2012 Jul; 26(7):1710-3.

Landau D, Carter S, Stojanov P, Stevenson KE, Mckenna A, Lawrence M, Sougnez C, Sivachenko A, Wang L, Zhang W, Sachet S, Vartanov AR, Fernandes SM, Cibulskis K, Tesar B, Gabriel S, Meyerson M, Lander ES, Neuberg DS, Brown JR, Getz G, Wu CJ. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. Cell. 2013 Feb 14;152(4):714-26.

Velez N, Pritesh K, Vartanov AR, Davids MS, Brown JR, Schmults CD. Association of Advanced Leukemic Stage and Skin Cancer Tumor Stage with Poor Skin Cancer Outcomes in Patients with Chronic Lymphocytic Leukemia. JAMA Dermatology. 2014 Mar 1;150(3):280-7.

Wang L, Shalek AK, Lawrence M, Ding R, Gaublomme JT, Pochet N, Stojanov P, Sougnez C, Shukla SA, Stevenson KE, Zhang W, Wong J, Sievers QL, Macdonald BT, Vartanov AR, Goldstein NR, Neuberg D, He X, Lander E, Hacohen N, Regev A, Getz G, Brown JR, Park H, Wu CJ. Somatic Mutation as a Mechanism of Wnt/B-Catenin Pathway Activation in CLL. Blood. 2014 Aug 14;124(7):1089-98.

Davids MS, Vartanov A, Werner L, Neuberg D, Dal Cin P, Brown JR. Controversial Fluorescence in situ Hybridization Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia: New Insight from a Large Cohort. British Journal of Hematology. 2015 Sep;170(5):694-703.

Davids MS, Kim HT, Yu L, De Maeyer G, McDonough M, Vartanov AR, Langey R, Fernandes SM, Hellman JM, Francoeur K, Arnason J, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR. Ofatumumab plus High Dose Methylprednisolone followed by Ofatumumab plus Alemtuzumab to Achieve Maximal Cytoreduction prior to Allogeneic Transplantation for 17p Deleted or TP53 Mutated Chronic Lymphocytic Leukemia. Leukemia Lymphoma. 2018 Oct 15:1-4.

Bell S, Lattanzio N, Braham J, Campdesuner V, Abdelal Q, Vartanov A, Pelayo M. An Unusual Case of Prolymphocytic Leukemia Transformation in a Patient with Chronic Lymphocytic Leukemia. Journal of Investigative Medicine High Impact Case Reports. 2021 Jan-Dec;9:2324709621990767.

Vartanov AR, Kalotra A, Varughese J, Kandel S, Gautam S, Hosmer W. Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review. Respiratory Medicine Case Reports. 2021 Mar 18;33:101390.

Vartanov AR, Lampson BL, Jacobsen ED, Alyea EP, Moslehi JJ, Brown JR. High-grade heart block associated with ibrutinib therapy. HeartRhythm Case Reports. 2021 Mar 19;7(6):391-394.

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...